Anteris Treats First Patients in Global DurAVR Heart Valve Pivotal Trial

Anteris Technologies has commenced enrollment and treatment of patients in its global pivotal PARADIGM Trial for the DurAVR Transcatheter Heart Valve, targeting severe calcific aortic stenosis. The trial, which began at Copenhagen University Hospital, aims to provide robust comparative evidence across all surgical risk groups to support commercialization and expand treatment options. The DurAVR THV is a biomimetic, balloon-expandable valve designed to mimic healthy aortic valve function, with prior success in 130 patients including complex cases such as bicuspid valves and valve-in-valve procedures. Anteris plans to expand the trial across the United States, Europe, and Canada, reflecting strong investigator enthusiasm. This head-to-head study is expected to differentiate the DurAVR platform based on efficacy, safety, and ease of use. The company operates globally with significant revenue from the U.S. and is focused on innovative structural heart solutions.